Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number to the paper to the pa

## POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM

Application Number	PCT/EP2004/011621		
Filing Date	11 October 2004		
First Named Inventor	Claudine Elvire Marie BRUCK		
Title	IMMUNOGENIC COMPOSITIONS		
Art Unit			
Examiner Name			
Attorney Docket Number	VB60529		

I hereby appoint:				
Practitioners associated with the Customer Number	ers. 20462			
Or				
☐ Practitioner(s) named below:				
Name		Registration Number		
		4 4 - 11 h i i - 4h -		
As my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the				
United States Patent and Trademark Office connected the	erewith.			
The state of the s		instinutos		
Please recognize or change the correspondence address for the above-identified application to:				
The address associated with the above-mentioned Customer Number:				
Or No. 1 2046				
The address associated with Customer Number 20	U402			
Or	<u></u>			
☐ Firm or Individual Name:				
Address:				
Address:				
City:	State:	Zip:		
Country:				
Telephone:	Fax:			
I am the:				
☐ Applicant/Inventor:				
Assignee or record of the entire interest. See 37 CFR 3.71.				
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)				
SIGNATURE of Applicant or Assignee of Record				
Signature: Marcus 12: Allen	Date: - 4 MAY 2006			
Name: Marcus Jonathan William DALTON	Telephone: +44 20 8047 4401			
Title and Company. GlaxosmithKline Biologicals SA and SmithKline Beecham Corporation				
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required.				
Submit multiple forms if more than one signature is required, see below*.				
☐ *Total of: forms are submitted.				

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CRF 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control numbers.

STATEMENT UNDER 37 CRF 3.73(b)			
Applicant/Patent Owner: GlaxoSmithKline Biologicals SA and SmithKline Beecham Corporation			
International Application No./Patent No.: PCT/EP2004/011621 Filed/Issue Date: 11 October 2004			
Entitled: IMMUNOGENIC COMPOSITIONS			
GlaxoSmithKline Biologicals SA and SmithKline Beecham Corporation, corporations, state that they are:			
1. \( \square\) the assignee of the entire right, title, and interest; or			
2.  an assignee of less than the entire right, title and interest.			
The extent (by percentage) of its ownership interest is 50% in the patent application/patent identified above			
by virtue of either;			
A. [] An assignment from the inventor(s) of the patent application/patent identified above. The assignment was			
recorded in the United States Patent and Trademark Office at Reel , Frame , or for which			
copy thereof is attached.			
OR			
•			
B. [] A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee			
as shown below:			
1. From: To:			
The document was recorded in the United States Patent and Trademark Office at			
Reel , Frame , or for which a copy thereof is attached.			
2. From: To:			
The document was recorded in the United States Patent and Trademark Office at			
Reel, Frame, or for which a copy thereof is attached.			
3. From: To:			
The document was recorded in the United States Patent and Trademark Office at			
Reel, Frame, or for which a copy thereof is attached.			
Additional documents in the chain of title are listed on a supplemental sheet.			
[X] Copies of assignments or other documents in the chain of title are attached.			
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment			
Division in accordance with 37 CRF Part 3, if the assignment is to be recorded in the records of the USPTO.			
See MPEP 302.08]			
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.			
1 8830 0000			
Marcus -4 MAY 2006			
Signature . Date			
Marcus Ionathan William DALTON +44 20 8047 4401			
Printed or Typed Name Telephone Number			
Attorney and Authorised Official			
Title			

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CRF 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.